Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Augmented BFM Therapy Plus Ofatumumab for Young Adults With ALL or LL
NCT02419469Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2015
- Primary completion
- Jun 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2015; status: terminated.
02
Drugs
ofatumumab
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02419469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419469.